Mission

A third of approved medicines act on G-protein–coupled receptors (GPCRs), yet today’s high-throughput screening assays cannot measure or predict how ligands activate these receptors.

GPCRs cycle through discrete conformations with distinct pharmacology that current in-vitro assays cannot resolve. To address this gap, we have built Conformational-Sequencing (ConfoSeq), the first live-cell assay that deconvolutes GPCR activation per conformation. ConfoSeq quantifies ligand potency, efficacy, and activity for each of the four canonical conformations. These 12 clean, state-resolved labels, that we call the conformational sequence, reveal how GPCR are activated and enable us to deterministically design and maximise in vitro GPCR drug efficacy.